Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXL01 with Nivolumab and FOLFOX in Advanced Gastric Cancer
NCT06253611Phase 2Recruiting
- Sponsor
- GERCOR
- Start
- Apr 2024
- Primary completion
- Sep 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of exl01 in gastric cancer (GC) (2 arms), sponsored by GERCOR. Primary endpoint: Objective Response Rate at 4 months. Started Apr 2024; status: recruiting.
02
Drugs
exl01
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06253611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253611.